Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | CCNB2 | O95067 | 5/20 | 0.40 |
| ▸ | CDK1 | P06493 | 5/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.40 |
| ▸ | GSK3B | P49841 | 5/20 | 0.40 |
| ▸ | CCNB3 | Q8WWL7 | 5/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 5/20 | 0.40 |
| ▸ | GSK3A | P49840 | 4/20 | 0.40 |
| ▸ | PRKCI | P41743 | 2/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29487153 | 1.00 | PARP1 (0.45) | PARP1HTTDAOCCNB2CDK1 | |
| SCHEMBL1665498 | 0.80 | PARP1 (0.42) | PARP1CCNB2CDK1CCNB1GSK3B | |
| SCHEMBL1058944 | 0.78 | CCNB2 (0.38) | PARP1HTTCCNB2CDK1CCNB1 | |
| SCHEMBL4365192 | 0.78 | KDM4C (0.41) | DAOCCNB2CDK1CCNB1GSK3B | |
| SCHEMBL17645730 | 0.77 | DAO (0.42) | DAOCCNB2CDK1CCNB1GSK3B | |
| SCHEMBL20449743 | 0.77 | DAO (0.42) | PARP1DAOCCNB2CDK1CCNB1 | |
| SCHEMBL4371769 | 0.77 | GAA (0.41) | HTTDAOCCNB2CDK1CCNB1 | |
| SCHEMBL22304188 | 0.74 | GSK3A (0.36) | PARP1CCNB2CDK1CCNB1GSK3B | |
| SCHEMBL29100896 | 0.74 | DAO (0.56) | PARP1DAOGSK3BCDK5GSK3A | |
| SCHEMBL8972110 | 0.74 | KDM4C (0.39) | HTTDAOCCNB2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404279-B2 | Deubiquitinase inhibitors and methods of use thereof | MOLECURE S.A. (PL) | 2025-09-02 | — | — | US | disclosed |
| US-20230219973-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | MOLECURE S.A. (PL) | 2023-07-13 | — | — | US | disclosed |
| US-20230219973-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | MOLECURE S.A. (PL) | 2023-07-13 | — | — | US | disclosed |
| WO-2023119233-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | MOLECURE S.A. (PL) | 2023-06-29 | — | — | WO | disclosed |
| US-20230022091-A1 | COMPOUND FUNCTIONING AS BROMODOMAIN PROTEIN INHIBITOR, AND COMPOSITION | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| US-11466034-B2 | Compound functioning as bromodomain protein inhibitor, and composition | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2022-10-11 | — | — | US | disclosed |
| US-20220235064-A1 | OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | WELLMARKER BIO CO., LTD. (KR) | 2022-07-28 | — | — | US | disclosed |
| EP-4011885-A1 | OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Wellmarker Bio Co., Ltd. (KR) | 2022-06-15 | — | — | EP | disclosed |
| EP-4011885-A1 | OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Wellmarker Bio Co., Ltd. (KR) | 2022-06-15 | — | — | EP | disclosed |
| CN-110114357-B | Hetero-bicyclic compounds useful as modulators of IL-12, IL-23, and/or IFN alpha response | 百时美施贵宝公司 | 2022-05-31 | — | — | CN | disclosed |
| EP-3719017-A2 | COMPOUND FUNCTIONING AS BROMODOMAIN PROTEIN INHIBITOR, AND COMPOSITION | Betta Pharmaceuticals Co., Ltd. (CN) | 2020-10-07 | — | — | EP | disclosed |
| US-10781215-B2 | Heterobicyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-09-22 | — | — | US | disclosed |
| US-10781215-B2 | Heterobicyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-09-22 | — | — | US | disclosed |
| US-20190322672-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2019-10-24 | — | — | US | disclosed |
| US-20190322672-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2019-10-24 | — | — | US | disclosed |
| EP-3532473-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | Bristol-Myers Squibb Company (US) | 2019-09-04 | — | — | EP | disclosed |
| WO-2018081488-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-03 | — | — | WO | disclosed |
| WO-2018081488-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-03 | — | — | WO | disclosed |
| WO-2008144253-A1 | PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF | IRM LLC (BM) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008144253-A1 | PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF | IRM LLC (BM) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11466034-B2 | Compound functioning as bromodomain protein inhibitor, and composition | BRD4, BRD1, BRD2 | PARP1 191/4885HTT 1020/4885DAO 4360/4885 |
| US-10781215-B2 | Heterobicyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses | TYK2, IL2, IL23R | PARP1 1523/4885HTT 2911/4885DAO 3508/4885 |
| US-20220235064-A1 | OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ROS1, ROR1, RET | PARP1 3153/4885HTT 4314/4885DAO 3100/4885 |
| US-20230022091-A1 | COMPOUND FUNCTIONING AS BROMODOMAIN PROTEIN INHIBITOR, AND COMPOSITION | BRD4, BRD1, BRD2 | PARP1 191/4885HTT 1020/4885DAO 4360/4885 |
| US-20190322672-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | TYK2, IL2, IFNG | PARP1 1695/4885HTT 2845/4885DAO 2986/4885 |
| US-20230219973-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | USP7, USP28, USP1 | PARP1 1236/4885HTT 274/4885DAO 2542/4885 |
| US-12404279-B2 | Deubiquitinase inhibitors and methods of use thereof | USP7, USP28, USP1 | PARP1 1236/4885HTT 274/4885DAO 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.